Candid Therapeutics and UCB: When China-Origin Assets Become Global Strategy

UCB’s planned acquisition of Candid Therapeutics for up to US$2.2 billion is more than a large biotech M&A deal. It is a good example of how China-origin assets can be repositioned into a globally attractive platform story.

Candid’s lead asset, cizutamig / CND106, originally came from EpimAb as EMB-06, a BCMA×CD3 bispecific antibody developed for multiple myeloma. In oncology, it would have faced a crowded competitive landscape. Candid changed the story by repositioning the same mechanism toward autoimmune diseases, where deep B-cell and plasma-cell depletion could support a broader immune-reset strategy.

This is the most interesting part of the case. The value was not created simply by licensing an asset from China. It came from changing the development context around the asset: a new indication strategy, a stronger global company structure, experienced leadership, financing, CMC preparation, and a broader T-cell engager platform vision.

Candid also used geography thoughtfully. China appears to have played an important role in early autoimmune clinical execution across multiple indications, while Australia studies helped support route-of-administration optimization, including IV-versus-subcutaneous development. Together, this created a more global and commercially relevant development package.

The WuXi Biologics collaboration further expanded the platform beyond two initial assets by adding next-generation trispecific T-cell engager capability. This helped Candid look less like a single-asset repositioning company and more like an autoimmune TCE platform.

For me, the key takeaway is simple: China-origin assets do not create value automatically. The real value comes from how those assets are selected, repositioned, clinically developed, and packaged into a global strategy.

Candid is a thoughtful example of that transition.